Wolfgang Weber

Closest collaborators

The 15 strongest of 15 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

1. Neeta D. Pandit-Taskar · 1 shared paper, 1 shared grant, 2019
   • Grant Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer R01CA222049↗
   • Paper Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Ima… DOI 10.1158/1078-0432.ccr-18-3667↗
2. Jason Stuart Lewis · 1 shared paper, 1 shared grant, 2019
   • Grant Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer R01CA222049↗
   • Paper Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Ima… DOI 10.1158/1078-0432.ccr-18-3667↗
3. Michael Ian D'Angelica · 1 shared grant, 2019
   • Grant Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer R01CA222049↗
4. Katrin J. Frank · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
5. Marina Lesina · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
6. Kıvanç Görgülü · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
7. Derya Kabacaoğlu · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
8. Antonio Mulero-Sánchez · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
9. Dietrich Alexander Ruess · 1 shared paper, 2022
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
10. René Bernards · 1 shared paper, 2022
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
11. Sara Mainardi · 1 shared paper, 2022
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
12. Bruno Sáinz · 1 shared paper, 2022
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
13. Hana Algül · 1 shared paper, 2022
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
14. Christian Lohrmann · 1 shared paper, 2019
    • Paper Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Ima… DOI 10.1158/1078-0432.ccr-18-3667↗
15. Eileen Mary O'Reilly · 1 shared paper, 2019
    • Paper Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Ima… DOI 10.1158/1078-0432.ccr-18-3667↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.